HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphism

Journal of Viral Hepatitis

Volumn 20, Issue 3, 2013, Pages 193-199

  Stenkvist, J ^a   Sonnerborg A ^a   Weiland, O ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

HCV RNA; Hepatitis C virus; IL28B; peg IFN; ribavirin

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; RAPID VIRAL RESPONSE; SINGLE NUCLEOTIDE POLYMORPHISM; SUSTAINED VIRAL RESPONSE; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; COINFECTION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERONS; INTERLEUKINS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RIBAVIRIN; RNA, VIRAL; STANDARD OF CARE; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84873464921     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2012.01645.x     Document Type: Article

References (24)

1. Volk ML, Tocco R, Saini S, Lok AS,. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009; 50: 1750-1755.
2. Weber R, Sabin CA, Friis-Moller N, et al,. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 1632-1641.
3. Cardoso AC, Moucari R, Figueiredo-Mendes C, et al,. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010; 52: 652-657.
4. Falconer K, Sandberg JK, Reichard O, Alaeus A,. HCV/HIV co-infection at a large HIV outpatient clinic in Sweden: feasibility and results of hepatitis C treatment. Scand J Infect Dis 2009; 41: 881-885.
5. Fried MW, Shiffman ML, Reddy KR, Jr et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
6. Manns MP, McHutchison JG, Gordon SC, et al,. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
7. Ge D, Fellay J, Thompson AJ, et al,. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
8. Rallon NI, Naggie S, Benito JM, et al,. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010; 24: F23-F29.
9. Thomas DL, Thio CL, Martin MP, et al,. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
10. Thompson AJ, Muir AJ, Sulkowski MS, et al,. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-129.
11. Lagging M, Askarieh G, Negro F, et al,. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS ONE 2011; 6: e17232.
12. Mangia A, Thompson AJ, Santoro R, et al,. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 821-827.
13. Sarrazin C, Susser S, Doehring A, et al,. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011; 54: 415-421.
14. Scherzer TM, Hofer H, Staettermayer AF, et al,. Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. J Hepatol 2011; 54: 866-871.
15. Moghaddam A, Melum E, Reinton N, et al,. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 2011; 53: 746-754.
16. Karlstrom O, Sonnerborg A, Weiland O,. Similar hepatitis C virus RNA kinetics in HIV/hepatitis C virus monoinfected genotype 2 or 3 matched controls during hepatitis C virus combination therapy. AIDS 2008; 22: 899-901.
17. Nilsson J, Weiland O,. Effect of control selection on sustained viral response rates in genotype 2/3 HCV mono-infected vs HIV/HCV co-infected patients. Scand J Infect Dis 2010; 42: 533-539.
18. Weiland O, Hollander A, Mattsson L, et al,. Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin. J Viral Hepat 2008; 15: 641-645.
19. Lagging M, Wejstal R, Uhnoo I, et al,. Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations. Scand J Infect Dis 2009; 41: 389-402.
20. Sizmann D, Boeck C, Boelter J, et al,. Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS((R)) AmpliPrep/COBAS((R)) TaqMan((R)) System. J Clin Virol 2007; 38: 326-333.
21. Yun Z, Lara C, Johansson B, Lorenzana de Rivera I, Sonnerborg A,. Discrepancy of hepatitis C virus genotypes as determined by phylogenetic analysis of partial NS5 and core sequences. J Med Virol 1996; 49: 155-160.
22. Shin WG, Park SH, Jang MK, et al,. Aspartate aminotransferase to platelet ratio index (APRI) can predict liver fibrosis in chronic hepatitis B. Dig Liver Dis 2008; 40: 267-274.
23. Westin J, Ydreborg M, Islam S, et al,. A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection. Scand J Gastroenterol 2008; 43: 73-80.
24. Lindh M, Lagging M, Farkkila M, et al,. Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. J Infect Dis 2011; 203: 1748-1752.